Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4098S | ISIN: US6963894026 | Ticker-Symbol: 7NS0
NASDAQ
05.06.25 | 22:00
0,698 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PALISADE BIO INC Chart 1 Jahr
5-Tage-Chart
PALISADE BIO INC 5-Tage-Chart

Aktuelle News zur PALISADE BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.Palisade Bio meldet positive Phase-1-Ergebnisse für neues Medikament-
27.05.Palisade Bio reports positive Phase 1 results for new drug1
27.05.PALISADE BIO, INC. - S-1, General form for registration of securities1
27.05.Palisade Bio, Inc.: Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis149Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs...
► Artikel lesen
PALISADE BIO Aktie jetzt für 0€ handeln
12.05.PALISADE BIO, INC. - 10-Q, Quarterly Report1
06.05.Palisade Bio's PALI-2108 shows promise in ulcerative colitis study1
02.05.PALISADE BIO, INC. - 8-K, Current Report2
01.05.Palisade Bio, Inc.: Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit2
09.04.Palisade Bio reports safe PALI-2108 trials, eyes H1 2025 data2
09.04.Palisade Bio, Inc.: Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108277Sustained positive preliminary data from all completed single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and food effects crossover, further supporting the safety and tolerability...
► Artikel lesen
24.03.PALISADE BIO, INC. - 10-K, Annual Report2
14.03.Palisade Bio, Inc.: Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108161Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious...
► Artikel lesen
12.03.Palisade Bio to present ulcerative colitis treatment data2
12.03.Palisade Bio präsentiert Daten zur Behandlung von Colitis ulcerosa7
12.03.Palisade Bio, Inc.: Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 20251
04.03.Palisade Bio, Inc.: Palisade Bio Participates in Virtual Investor "What This Means" Segment2
20.02.Palisade Bio sichert sich kanadische Steuergutschrift für Medikamentenstudie1
20.02.Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)1
10.02.Palisade Bio, Inc.: Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis184Data presented at the 2025 Crohn's and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company...
► Artikel lesen
29.01.Palisade Bio, Inc.: Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress2
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1